Evaluating the effect of imatinib mesylate in chronic myeloid leukemia patients in the expression of JunB and BCR-ABL gene
碩士 === 高雄醫學大學 === 醫學研究所 === 91 === Imatinib mesylate, a potent inhibitor of the Bcr-Abl tyrosine kinase that is central to the pathogenesis of CML, has demonstrated remarkable hematologic and cytogenetic response especially in chronic phase. This was well documented in various studies inc...
| Main Authors: | , |
|---|---|
| Other Authors: | |
| Language: | zh-TW |
| Published: |
2003
|
| Online Access: | http://ndltd.ncl.edu.tw/handle/xda47d |